Immunic schedules November investor relations circuit
Biotech firm Immunic will host a virtual R&D event and attend multiple international healthcare investor conferences throughout November.
Immunic, Inc. has confirmed its participation in a series of healthcare investor conferences this November. CEO Erik Lundgren and President/COO Jason Tardio are scheduled to present at both the Guggenheim Healthcare Innovation Conference in Boston and the Stifel Healthcare Conference in New York. The company will also conduct private meetings with investors during the Jefferies Global Healthcare Conference in London.
In addition to these financial events, the company is hosting a virtual R&D day on November 5. The session, focused on progressive multiple sclerosis, will feature external subject-matter experts discussing current therapeutic gaps and future treatment development.
Immunic is currently developing vidofludimus calcium (IMU-838), an oral therapy candidate currently in Phase 3 clinical trials for relapsing multiple sclerosis. Top-line data for this program is anticipated by the end of 2026, with an additional Phase 3 trial for progressive multiple sclerosis expected to initiate before year-end.